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The thymidine analog 5-bromodeoxyuridine (BrUdR) incorporated into DNA
has been successfully used as a selective agent (1, 2) or mutagen (3) on various
animal cells. Some of its effects are understandable in terms of base substitution
in the genetic material; others, however, such as the reversible suppression of cyto-
differentiation (4-7), remain unexplained.
We have examined the effects of prolonged treatment with high BrUdR concen-
trations on the in vitro and in vivo characteristics of a murine malignant melanoma
(B16) cell line and have already reported the isolation and altered phenotype of
B16 cells tolerant to 45 /Ag BrUdR/ml (8). Moreover, these did not require con-
tinued exposure to the analog-containing environment (9). The data presented here
review and extend our previous observations and support the hypothesis that B16
cells tolerant to high analog doses (1) are stable amelanotic variants and (2) do
not retain their altered phenotype by virtue of residual BrU-DNA. We also demon-
strate, by means of cesium chloride (CsCl) equilibrium-centrifugation analysis, that
tolerant cells incorporate less analog into DNA than control cells. When cells
chronically exposed to BrUdR were tested in vivo, tumorigenicity was reduced but
not completely extinguished. On the other hand, cells withdrawn from the
BrUdR-containing media eventually become as tumorigenic as control cells.
MATERIALS AND METHODS
Cells. B16 malignant melanoma developed spontaneously in a C57BL mouse
at the Jackson Laboratory in 1954 (10). In 1964, two cell strains, HFH-14 and
HFH-18, were established in vitro (11). A pigmented cell line, 440B, derived from
one of these strains (HFH-18) was used almost exclusively in the present studies.
Chart 1 gives a detailed history of this cell line. As a monolayer culture, it prolifer-
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ates equally well in Medium 199 or in Eagle's Minimal Essential Medium (MEM)
supplemented with 10% fetal-calf serum and antibiotics. Media and serum were
purchased from Grand Island Biological Co. (Grand Island, NY).
A detailed history of cells chronically treated with the thymidine analog
5-bromodeoxyuridine (BrUdR) (California Biochemicals) is given in Chart 2
(Group 1 cells). We began by exposing mass cultures of 440B growing in MEM
to increasing concentrations of the analog in November, 1969, initiating the regi-
men with 3 ,ag/ml, and raising it first to 6 ,ug/ml and then to 10 jug/ml. Thereafter
the cells were cultured in media containing BrUdR at 2 ,ug/ml increments up to
20 ,fg/ml and 5 ug/ml increments up to 45 jug/ml. In March, 1972, we increased
the dosage to even larger increments and presently maintain three sublines in 45
jug/ml, 300 jug/ml, and 500 ,ug/ml BrUdR, respectively.
Chart 3 outlines the history of cells propagated in MEM containing 10 ug
BrUdR/ml, recultured in analog-free MEM for 4 months, and then injected into
mice. Cells from these tumors were subsequently reestablished in vitro in MEM
for 8 months when an additional subline was started in Medium 199 (Group 2
cells).
Group 3 cells (Chart 4) are those that had been growing in MEM with a final
concentration of 30 ,ug BrUdR/ml and were then transferred to analog-free MEM
for 5 months. At that time, an additional line was established in Medium 199 which
also lacked the analog. Both of these lines are called "released" cells.
NP, an amelanotic cell line, was established in culture from a nonpigmented
tumor produced by the injection of cells of a nonpigmented HFH-18 subline (12).
Cytological examination. To inspect cellular morphology, we seeded cells onto
a 22 X 45-mm coverglass in a 60 X 15-mm Falcon plastic culture dish or a two-
chambered slide (Lab Tek, Miles Laboratory, Westmount, IL). When they had
grown to a confluent sheet, the cells were rinsed in isotonic saline, fixed in metha-
nol, and stained with May-Griinwald-Giemsa.
We continuously observed the morphology of all cells but include here only
representative samples from different monitorings.
Tumor production. Tumors were established at several different times by sub-
cutaneously injecting cells suspended in 0.2 ml phosphate-buffered saline into
6-week-old male C57BL/6 mice. The number of cells, as well as of mice tested,
varied. Tables 1 and 2 and legends to Charts 2-4 give the figures for each test.
Density gradient centrifugation studies. Approximately 106 cells were subcul-
tured into 250-ml flasks (Falcon Plastics). Twenty-four hours later, 45 jug/ml
BrUdR were substituted for the MEM in control cultures of "acute-45" cells,
whereas "chronic-45," "chronic-500," control, and "released" cells were fed 45
,zg/ml BrUdR, 500 /ig/ml BrUdR, and MEM, respectively. The released cells used
were transferred from 30 ,ug BrUdR/ml into MEM and proliferated in the analog-
deficient medium for 2 years. After feeding, 1 ,uCi/ml 3H-deoxyadenosine (G)
(11.1 Ci/mmole) or 0.05 MuCi/ml, 14C-deoxyadenosine-8 (38.8 mCi/mmole)
(both from New England Nuclear, Boston, MA) were added. Twenty-four to 28
hr later, the cells were trypsinized, centrifuged, and washed three times with Hanks'
balanced salt solution.
DNA was extracted from the different classes of cells, generally 3-5 X 106 cells
per class, by a modification of the procedure of Penman (13). Each cell group
CHART 1. In vitro and in vivo history of 440B and P 51 cells.
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CHART 2. In vitro and in vivo history of 440B cells continuously cultured in BrUdR
(Group 1 cells). a = 69 and b = 45 amelanotic tumors.
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TABLE 1
TUMORIGENICITY OF BrUdR-TREATED AND UNTREATED B16 CELLS
No. cells Days postinjection tumors were
Cells injected Palpable Visible Tumor weight (g)a
Untreated 440B 106 14 (10/1O)b 18 (10/10) 2.5 ± 0.37 (20d)c
5 X 106 10-12 (5/5) 14-15 (5/5) 4.0 ± 0.43 (20d)
Untreated NP 106 14 (10/10) 18 (10/10) 2.8 ± 0.9 (20d)
440B Chronically 106 (3/22/72) 79 (5/5) 87 (1/5); 0.6 ± 0.10 (161d)
treated with 45 106 (8/30/72) 41 (10/10) 112 (4/5)
Ag BrUdR/ml 55 (10/10) 3.4 ± 1.(0 (55d)
3 X 106 (4/25/72) 23 (5/5) 40 (5/5) 5.0 ± 0.70 (51d)
B X 106 (6/23/72) 21 (10/10) 35 (10/10) 6.0 ± 0.90 (51d)
a = mean ± SD; b = number of tumors/number of mice injected; c = day postinjection.
TABLE 2
TUMORIGENICITY OF CELLS CHRONICALLY TREATED WITH BrUdR AND TRANSFERRED TO MEM
BrUdR Number of Days postinjection tumors were
concentration Time in MEM cells Palpable Visible Tumor weight (g)a
30 ,ug/ml 5 months 5 X 106 12 (10/lO)b 16 (10/10) Not determined
(10 mos)
45 pg/ml 7 days 106 42 (7/9) 54 (9/9) 2.9 ± 1.1 (54)c
(2 yrs 7 mos)
14 days 106 41 (9/10) 51 (10/10) 3.9 ± 0.83 (56)
21 days 106 38 (7/8) 46 (8/8) 4.0 ± 0.96 (53)
a = mean + SD; b = number of tumors/number of mice injected; c = day postinjection.
was pooled as a frozen pellet, with 2-5 vol of unlabeled BCS-1 (Green monkey
kidney) cells for carrier. The extraction was performed on whole cells rather than
separated nuclei, and the treatment with deoxyribonuclease was omitted. The aque-
ous phase from the last chloroform-isoamyl alcohol extraction was made 1 M with
respect to NaCl, the RNA precipitate was centrifuged to a pellet, and DNA was
spooled from the supernatant under 2 vol of ethanol. This spooled DNA was redis-
solved in 0.1 X SSC (1.5 X 10-2 M sodium chloride + 1.5 X 10-3 trisodium ci-
trate, pH 7.0) and used without further treatment.
Samples of the labeled DNA were mixed with a stock cesium chloride solution
in 0.1 X SSC in combinations shown in Fig. 9a-e to give a volume of 3 ml and
a density of approximately 1.72. These were centrifuged under oil for 60-70 hr,
at 30,000 rpm in a SW 39 rotor at 200C. Fractions were collected from below,
densities determined pycnometrically with a calibrated micropipet, and aliquots of
each fraction assayed in a scintillation counter. Double-label separation and nor-
malized plotting were done by computer.
RESULTS
In vitro studies. The morphology of the two untreated cultures, 440B and NP,
is illustrated in Figs. 1 and 2, respectively. The former are lightly pigmented
in vitro whereas the latter are amelanotic but both are spindle-shaped, lack contact
CHART 4. In vitro and in vivo history of cells transferred from 30 ,g BrUdR/ml into
analog-free media (Group 3 cells). a = 10, b = 15, c = 20, d = 46.e = 120, and f = 54
amelanotic tumors.
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FIGS. 1-8. Morphological aspects of cells in vitro stained with May-Grunwald-Giemsa. All
figures X 160.
FIG. 1. Untreated 440B cells.
FIG. 2. Untreated NP cells.
FIG. 3. Cells grown for 2 years 8 months in BrUdR (final concentration: 45 ,ug/ml). See
Chart 2.
FIG. 4. Cells grown for 2 years 6 months in BrUdR (final concentration: 500 ug/ml).
See Chart 2.
inhibition, and pile high on each other. At doses as low as 3 jug/ml BrUdR, the
cellular morphology of 440B altered, and continued to do so, as we increased exp-
posure to the analog. Cells maintained in medium containing BrUdR were more
contact inhibited than control cells but, to some extent, still formed multilayered
areas. Moreover, they were greatly enlarged, unpigmented, and flattened. These
morphological changes persisted as the analog concentration was increased and
are apparent in cultures currently maintained in 45 Lg/ml (Fig. 3) or 500 ,g/ml
BrUdR (Fig. 4).
With one exception, all cultures transferred into MEM (Fig. 5) or Medium 199
(Fig. 6) from 10 jug BrUdR/ml were morphologically similar to group 1 and 2
cultures. In February 1971, we observed small colonies of small, spindle-shaped,
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pigmented cells among the enlarged, flattened amelanotic cells. Only one bottle of
this subline survived at that time and in it only the larger, amelanotic cells prolifer-
ated. Although continuously maintained in analog-free medium since then, the
smaller, pigmented cells have not been detected again.
4A'
. ts ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~A
;M^M_i:#*:;1.~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Fio. 5. Cells grown in BrUdR (final concentration: 10 ,ug/ml) for 7 months and transferred
to analog-free MEM for 4 months. After 1 passage in vivo, they were reestablished in
culture in analog-free MEM for 1 year 10 months. See Chart 3.
FIG. 6. Cells grown in BrUdR (final concentration: 10 ,tg/ml) for 7 months and transferred
to analog-free MEM for 4 months. After one passage in vivo they were reestablished in
culture in analog-free MEM for 8 months and then transferred to analog-free Medium
199 for 1 year 4 months. See Chart 3.
FIG. 7. Cells grown in BrUdR (final concentration: 30 jug/ml) for 10 months and transferred
to analog-free MEM for 8 months. They then underwent two passages in vivo before they
were reestablished in culture. Then, after 2 additional months in analog-free medium, they
underwent two more passages in vivo and were reestablished in vitro in analog-free MEM
for 13 more months. See Chart 4.
FIG. 8. Cells grown in BrUdR (final concentration: 30 ,ug/ml) for 10 months and transferred
to analog-free MEM for 5 months. They were frozen in liquid nitrogen and after 4 months
thawed, reestablished in MEM for 1 month, and transferred to Medium 199 for 1 year
4 months. See Chart 4.
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After repeated subcultures in BrUdR-free media for more than 2 years, group
3 cells retained their enlarged, somewhat flattened, unpigmented phenotype. These
cells are similar (Figs. 7 and 8) to those of group 1 (Figs. 3 and 4) and group
2 (Figs. 5 and 6). No morphological differences were detected between cells grown
in MEM or Medium 199.
In vivo studies. All of the 114 tumors derived from cells chronically treated
with BrUdR were completely amelanotic (Chart 2). Furthermore, tumor detection
was much more delayed than in completely pigmented tumors produced by theBR UDR-TOLERANT MELANOMA CELLS
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injection of untreated 440B cells or in totally unpigmented tumors resulting from
untreated NP cells (Table 1). Both of the untreated cell lines, whether pigmented
or nonpigmented, generated tumors palpable by Day 14 and visible by Day 18
after subcutaneous injection of 106 cells. By contrast, when tested in March, 1972,
tumors from cells chronically treated with 45 ug BrUdR/ml were delayed as long
as 112 days and at the time of termination weighed considerably less than those
resulting from control cell inocula. However, 5 months later the same cell number
produced palpable tumors by Day 41 and visible tumors by Day 55 after injection.
Even when mice were inoculated with 3 X 106 or 5 X 106 BrUdR-tolerant cells,
tumors were not visible until 40 and 35 days, respectively.
Of the 424 tumors produced by cells transferred to analog-free media from
medium containing 10 jug BrUdR/ml (Chart 3), only 10 had small pigmented
nodules embedded in nonpigmented tumor tissue. We also observe a mixture
of small melanotic and large amelanotic cells growing simultaneously in our cul-
tures (see Results, In Vitro Studies).
When cells withdrawan from 30 ug BrUdR/ml and subsequently subcultured
in MEM were inoculated into C57BL/6 mice (Chart 4), 265 totally nonpigmented
tumors resulted.
In a limited study of the time required for cells tolerant to BrUdR and reduced
in tumorigenic potential to reach the same level of tumorigenicity as control cells
(Table 2), we found that cells proliferating in BrUdR for 10 months with a final
concentration of 30 jug/ml and transferred to MEM were as tumorigenic as controls
after 5 months (Table 1). Recently we have subcultured cells from 45 jug/ml
BrUdR into MEM and tested them in vivo 1, 2, and 3 weeks later (Table 2).
Clearly, this time span is not sufficient to completely reverse the suppression of
tumorigenicity to that of untreated 440B cells; however, all tumors in these tests
were completely amelanotic.
Density gradient centrifugation studies. Figure 9 a-e shows the buoyant density
profiles of DNA isolated from 440B, chronic and acute-45, chronic-500, and re-
leased cells tested in paired cultures. Cells treated with BrUdR for 2 years 9
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than untreated cells (p = 1.697) but not as much as control cells exposed for only
months (1 year 2 months in 45,Ag/ml) incorporated more analog (p = 1.714)
one generation time (p = 1.749) to the same drug dose. Significantly, both re-
leased cell and control cell DNA had the same buoyant density. Although the
BrUdR exposure to chronic-500 cells was more than 10 times that to chronic-45
cells, the DNA buoyant density of the former (p = 1.719) is somewhat larger than
that of the latter (p = 1.713) but not as great as that of DNA from acute-45
cells (p = 1.749).
The bands of DNA from both chronic-45 and chronic-500 cells were broader
than the band of normal DNA, and showed a prominent shoulder or small peak
on the light side. This broadening of the main peak suggests a heterogeneity in
density, and the light peak may be related to satellite DNA. This would be a large
peak for satellite, but it should be remembered that we measured the uptake of
exogenous deoxyadenosine, not the optical absorbance (mass) of the DNA. These
are not necessarily the same. Further experiments will be required to analyze the
broad, asymmetric distribution of DNA from BrUdR-tolerant cells.
DISCUSSION
Our results suggest that changes in the in vitro phenotype of 440B cells culti-
vated in and tolerant to high BrUdR concentrations are irreversible and indepen-
dent of continued analog exposure. Three independent lines of evidence support
this hypothesis. First, the altered morphological characteristics and pigment loss
persisted when tolerant cells were continuously subcultured in BrUdR-free medium
for 2 years. We believe that the putative revertant cells that were mixed with the
enlarged, amelanotic cells originated by contamination with non-BrUdR-treated
control cells. Since we have not detected such revertants either in vitro or in vivo
since February, 1971, this explanation seems justified.
Second, we depleted the tolerant cell BrU-DNA by injecting cells into host ani-
mals. In our experience, even though untreated 440B cells are lightly or seemingly
nonpigmented in vitro, they always generate darkly pigmented tumors in vivo. Of
the 803 tumors produced by injecting mice with cells previously exposed to the
analog, 793 were completely amelanotic. The 10 exceptional tumors developed
from the contaminated cultures described above.
Third, density-gradient centrifugation data (Fig. 9c) confirm that there is no
residual BrU-DNA in cells retaining the altered phenotype.
Other results from CsCl density-gradient centrifugation experiments reveal that
tolerant cells incorporate less BrUdR into their DNA than do acutely exposed cells.
The amount of BrU substituted for T in the DNA of various cell classes can be
estimated. When completely substituted, E. coli DNA, which contains 25% T,
gives a buoyant density increase of 0.1 g/cc (14). Mouse DNA containing 28%
T (15) gives a shift of 0.112 g/cc when each T is replaced by BrU. In control
vs chronic-45 DNA, the shift is 0.017 (Fig. 9a) and the degree of substitution
approximately 15% of the total Ts. Similarly, the replacement in acute-45 and
chronic-500 DNA is 46% and 19%, respectively (Fig 9b,d). When the buyoant
densities of chronic-45 and chronic-500 DNA's spun together (Fig 9e) are com-
pared, only a 6% increase in substitution was observed. This, added to the 15%
replacement estimate for chronic-45 DNA, gives a value of 21% for chronic-500
DNA, in good agreement with the 19% calculated directly from density compari-
son of chronic-500 to control cell DNA. In summary, the maximum analog incor-
poration in cells chronically treated with BrUdR is only 21% of the total T com-
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pared with 46% calculated for DNA from control cells exposed for 24-28 hr to
45 ,ug/ml BrUdR. This confirms our autoradiographic data (8) and supports the
hypothesis that BrUdR-tolerant cells utilize much less analog than control cells.
How tolerance to as much substituted T as we calculated above is built up and
maintained remains a vexing problem. Mouse heterochromatin, usually considered
genetically inert, is satellite DNA, rich in AT sequences (16). Although hetero-
chromatic regions were localized only in the centromeric regions of nonmalignant
mouse cells, an SV 40-transformed mouse cell line possessed interstitial hetero-
chromatin as well (18). We have also observed interstitial heterochromatic regions
in control and tolerant 440B chromosomes (19). Whether the increase in modal
chromcsome number in tolerant cells (8) is sufficient to account for a significant
rise in the amount of heterochromatin and thus the availability of extra Ts that
could be replaced by BrU is not known. Since only 10% of the total normal mouse
DNA is heterochromatin, it alone would not be enough to incorporate all the BrU
estimated from our data.
Although BrUdR may have acted on nonnuclear entities, e.g., the cell mem-
brane, to produce our amelanotic cells, it is difficult to explain how these modifica-
tions could be perpetuated for so many cell generations.
It is important to realize that few cells survived the rigorous selection conditions
initially imposed on our cultures to obtain tolerant cells. Because the modified cell
type was observed early in analog treatment, it probably originated either from
the selection of a variant in the original cell population or from a mutation(s)
induced by the analog. On the basis of morphological differences and chromosomal
features (19), it appears to be an entirely different variant from NP.
Tolerant cells were not as tumorigenic in vivo as control cells but this character-
istic varied. Since BrUdR incorporation at low levels has been shown to modify
malignancy in amelanotic melanoma cells (7), the depressed tumorigenic potential
in tolerant cells may result from the small quantities of the analog incorporated
into the cell. This likelihood is supported by the fact that after 5 months in analog-
free medium tolerant cells regain a tumorigenicity level comparable to that of un-
treated control cells.
Although the morphology of BrUdR-tolerant and released cells is similar, the
former appear slightly larger and more flattened. This analog effect, which has been
noted on various cell types (7, 20, 21), suggests a general control mechanism in
the manufacture of cell-specific molecules. We suggest, as have others, that in sup-
pressing a special molecular species (21) (in this instance, one required for tumori-
genicity), BrUdR interferes with the manufacture of a common surface molecule,
or vice versa.
SUMMARY
Malignant melanotic melanoma (B16) cells propagated for almost 3 yr in high
BrUdR concentrations are tolerant to 500 jug/ml BrUdR. Tolerant cells-enlarged,
flattened, and nonpigmented in vitro-produce only amelanotic tumors in vivo.
These modifications in the B16 phenotype did not require continued exposure to
the analog but persisted when these cells were transferred to an analog-free me-
dium. The analog-containing environment was also eliminated by the injection of
cells into host animals. In more than 800 tumors, some representing 27 animal
passages, only 10 possessed pigmented nodules. All 10 originated from one culture
which probably had been contaminated with pigmented cells from control cultures.
Data from cesium chloride density-gradient centrifugation show that the altered
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morphology of cells withdrawn from BrUdR does not derive from residual BrU-
DNA. Furthermore, cells chronically treated with BrUdR incorporate much less
analog into DNA than control cells exposed to 45 jug/ml BrUdR for one generation
time.
Although tumorigenicity is less in tolerant cells than in control cells, it is not
completely destroyed; the reduction can be reversed by prolonged growth in me-
dium lacking the analog.
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